The main clinical message from the Five-Year Analysis of Murano Study

In this MEdtalk Aron Kater present the Five-year follow-up data from the MURANO trial, showing that fixed-duration 2-year treatment with venetoclax-rituximab overall demonstrated durable response. The Murano study evaluates the benefit of fixed-duration combination therapy with venetoclax and rituximab compared with treatment with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
The new data demonstrates a sustained PFS and OS benefit in the group of patients treated with venetoclax and rituximab compared to bendamustine in combination with rituximab.